 host earn call earlier morn js manag team fairli upbeat outlook compani note
 rais adjust div/acq oper sale grow th expect also rais
bottom end narrow ed ep rang despit addit headw ind fx
full note call coupl takeaw ay relat medic devic busi
manag encourag sequenti improv sale grow th rate adjust basi acquisit
divestitur fx continu look time market grow th rate
healthcar util trend js commentari bit mix estim hospit admiss increas
lab volum ere surgic procedur ere slightli posit preliminari estim indic slight
declin trend hospit admiss lab procedur flat surgic procedur expect increas close
 view trend ith surgic procedur favor rest sector compani report
orthoped believ narrow ing gap betw een market compani lose share
continu knee particular orthoped price across major product group remain headw ind orthotaxi robot
launch expect
robot verb complet preclin procedur develop sever procedur engag ith hundr
surgeon verb engag right ith notifi bodi regulatori pathw ay manag comment expect
launch also expect launch orthotaxi orthoped robot
somew hat surprisingli us erent question discuss around prospect
net/net believ result commentari bode ell read-thru other med-tech market check
earn preview date via link
pleas feel free reach ith question
 post host inform quarter ebsit includ present referenc today call see link
call note verbatim
pleas ith strong start confid health busi
demonstr abil consist deliv grow th hile execut lt strategi
pharmaceut grow th driven immunolog oncolog neurosci pulmonari hypertens portfolio on-going
invest pipelin coupl ith strong commerci execut around new product line extens allow
off-set eros biosimilar gener grow th driven volum rather price anoth quarter neg price
 transpar report avail ebsit click
consum remain focus competit grow th observ broad market soft quarter encourag abil
gain area like over-the-counter tylenol reclaim brand adult analges posit ell ith neutrogena ogc
medic devic continu make progress state goal improv perform excit auri health acquisit hich
strength result give confid broad base busi continu manag portfolio
 sale total increas y/i report oper sale ex-fx grow th us ou report
sale dow oper
adjust acquisit divestitur fx sale grow th us ou
adjust earn ep repres increas respect oper ep grew
note herein chang referenc oper ex-fx basi
consum sale billion overal market grow th categori particip slow ed slightli adjust
 addit grow ing share tylenol neutrogena grow ing share e-commerc channel outpac
grow th channel ith strong doubl digit grow th across region
beauti almost adjust divestitur acquisit prioriti brand deliv strong perform
neutrogena us grow ing share mani categori ou sale grow th strong across multipl region driven new launch
over-the-counter sale global adjust zarbe acquisit us over-the-counter share grow th outpac categori tylenol sale ere
includ consumpt grow th ith balanc grow th inventori build due suppli constraint ou grew
almost ith strong sale asia driven nicorett quickmist motrin pediatr rhinocort allergi grow th partial
off-set upper respiratori brand due soft cold season northern europ russia
babi care dow global declin us primarili aveeno channel shift market soft hile declin ou
primarili due retail destock ith babi brand relaunch johnson babi brand relaunch key market grow ing
china india canada us modest declin consist ith overal market declin
pharma sale ere billion ith doubl digit grow th key product favor price
adjust hich ad almost grow th ere prior period stelara invokana prior period ith
remicad even adjust still deliv market perform global
us sale ere us ou price impact us us grow th ex price adjust
 approxim slow er grow th driven first full quarter zytiga gener deliv global grow th competit level
despit signific biosimilar gener headw ind
oncolog grow th darzalex grew global grew us strong market grow th increas share
ou grew increas share gain imbruvica grew global market share gain market grow th us base
data across indic line therapi gain market share zytiga dow ith declin us driven
gener hich off-set ou strong sale grow th eu asia market grow th share gain launch uptak
erleada pleas ith gain market share pleas ith approv balversa last eek
immunolog grow th ith stelara grow th primarili crohn indic off-set remicad eros
remicad maintain volum share prior period price adjust impact grow th reimcad
stelara pleas ith uptak stelara crohn market share tremfya sale ere global strong
demand ith patient therapi share
neurosci paliperidon long act perform ell grow ing spravato esketamin approv fda march
cardiovascular declin primarili driven declin xarelto innovakana biosimilar procrit xarelto increas
share ever grow th off-set legisl rate along ith higher medicar part util rebat
higher donut hole util legisl rebat chang
pulmonari hypertens grow th strong grow th opsumit uptravi grow ing respect
benefit market penetr increas share expect tracleer declin due increas opsumit gener
medic devic sale ere dow adjust sale sale ere acceler vs adjust sale
grow th strong intervent solut vision advanc surgeri
intervent solut grew global strong ep busi gain market share new er
product offer robust cerenovu double-digit grow th global
vision grew driven contact lens global daili astigmat announc avail acuvu
orthoped close gap ith market grew global sequenti improv
hip grew line ith market us share gain ou primarili asia
trauma grew global market grow th ith strong adopt new er innov us grow th rate acceler
sequenti strong grow th asia declin emea due tender time impact ou
spine dow improv straight quarter stabil perform driven new product includ viper
prime pedicl screw degen
knee declin almost quarter hile us sale declin improv perform straight quarter
driven uptak attun revis system ou declin emea off-set grow th asia latam
price pressur impact categori orthoped stabl overal pure price spine hip trauma
knee
pleas ith surgeri advanc surgeri grew almost global lead biosurgeri endocutt
biosurgeri driven strong demand aid new innov surgicel pow der gener surgeri ound closur
sell day didnt signific impact expect impact subsequ quarter
estim hospit admiss increas lab volum ere surgic procedur ere slightli
posit preliminari estim indic slight declin trend hospit admiss lab procedur flat
surgic procedur expect increas close
adjust exclud intang special item ipr charg relat rite dow alio biopharma
adjust ep y/i adjust cc basi
cog sg improv due segment mix
invest competit level quarter higher year ago increas driven pharma
mileston includ argenix associ ith agreement higher invest portfolio
net interest low er due higher interest earn low er debt rate
adjust tax rate year ago consist ith full year expect rate
adjust incom tax segment consist y/i pharma margin dow due increas invest
 consum improv driven gain invest cz hold devic flat improv
wolk cfo financi commentari guidanc
net debt cash/secur debt
alloc capit reinvest busi top prioriti invest quarter increas driven
mileston payment invest advanc asset strengthen consum ith acquisit ci labo
dividend billion repurchas billion ith program complet announc program decemb
first quarter result elev confid perform strengthen outlook oper sale grow th result
 increas guidanc basi point reflect full year oper sale grow th oper grow th
fx impact increas plan absorb impact ith strength oper sale outlook report
sale stay fx use spot rate januari euro report sale still billion
incom royalti incom gains/loss item litig invest jjdc divestitur
asset sale rite-off increas incom year ithin one largest announc
divestitur asp busi hich close ill result increas high end oper rang per share
tighten rang report basi estim impact fx increas estim year
adjust ep guidanc consist ith januari
strength busi quarter make confid guidanc abl absorb fx headw ind invest
provid quarterli guidanc ould like provid qualit factor divestitur asp close april note
compris incom given minim asp sale fx still headw ind less
 highest sale quarter year difficult comp particularli ith biosimilar/gener eros expect acceler
auri deal surgic robot updat verb pleas elcom auri famili elcom dr fred
moll pioneer robot view auri highli complementari verb program ell orthoped program orthotaxi
revenu monarch pleas share revenu endolumin surgeri
incom might creat headwind think go forward
incom new rang par ith elev sale grow th ould look similar dynam
 ould otherw ise dilut abl off-set ith perform also incom lost us
abl manag provid consist earn grow th
guidanc year rais earlier last year what drive confid rais what chang
confid year januari forecast probabl higher end rang subsid closer also
strength core product darzalex imbruvica medic devic gotten number begin ith hich
good ere adjust grow th lead give confid us orthoped saw quarter grow th
posit sign ork
auri see prototyp platform auri real valu first gener monarch revenu endolumin
lung program earli detect make big deal outcom monarch enabl earlier diagnosi
activ develop program bring thing like ablat digit surgeri broader indic surgeri orthoped
verb last eek knock dow risk everi day complet preclin procedur develop sever
procedur engag ith hundr surgeon engag right ith notifi bodi regulatori
pathw ay ould say stay tune take best insight fred moll make sure highli differenti program
ortho perform market growth share dynam knee consid knee perform stabil post declin
quarter us declin ou driven emea due predominantli one-tim commit get data
attun perform attun revis perform ell launch cementless offer later year
pharma market medicar part reform shift away drug rebat overtim realli support rebat reform
find ay get dollar discount back patient pocket cost caus pain market place
support administr effort rebat reform look forw ard patient afford cost
tremfya see competit landscap psoriasi tremfya global perform ell market
clinic data compar data reinforc true lead brand psoriasi show perform rapidli
patient great durabl ell data show ing better competit
margin slight improv look opportun invest ill see impact thing like suppli chain initi
beyond
consum expect market rebound littl bit estim full year market hich compet around market
grow th quarter market closer
vision care better contact lens market share relat meaning new lens oasi transit
 ith light manag pleas ith cl perform year market perform strong ou perform ell
innov drive market healthi perform market
think updat guidanc confid januari term confid see year
unfold zytiga held small molecul expect acceler that comparison brand grow ing
tracleer velcad see gener procrit eros biosimilar manufactur issu remedi
esketamin increment color center certifi dose anyth els share receiv approv launch
spravato quarter product avail ith rem program requir certifi site enrol patient rem
program interest realli high insur plan provid patient latest number actual site
certifi
xarelto increas donut hole expens greater percentag medicar medicaid hich heavili discount
invokana recent result show low er risk renal failur
pulmonari hypertens trajectori pah grew doubl digit increas optsumit uptravi deliv
million sale opsumit uptravi think uptravi signific driver busi grow th come
continu share gain market penetr earlier use
medic devic ant market look horizon see market better quarter
arent alw ay linear improv y/i grow th acceler hat plan see
consum see deceler quarter season structur portfolio over-the-counter see comparison ith flu
season babi saw deceler inter hich effect inter relat product impact destock
retail geographi broadli base across geographi expect soft rebound balanc
year hit project grow th market compet year
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
